18 May 2013
Keywords: enthusiasm, amgen, obesity, drug, palls, platform, technology
Article | 12 February 1996
Amgen's platform technology in its anti-obesity program, the ob gene and
its peptide product leptin, may not be the potential ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
12 February 1996
17 May 2013
© 2013 thepharmaletter.com